Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients receiving additional induction chemotherapy
Jia‐Wei Lv(Sun Yat-sen University), Ying Sun(Key Laboratory of Guangdong Province), Guan‐Qun Zhou(Sun Yat-sen University), Zhenyu Qi(University of Arizona), Xiaojun He(Harbin Medical University), Ling‐Long Tang(Sun Yat-sen University), Yan‐Ping Mao(Sun Yat-sen University), Lei Chen(Zhuzhou Central Hospital), Jun Ma(Shanghai Institute of Technology), Yu‐Pei Chen(Sun Yat-sen University), Wen‐Fei Li(Sun Yat-sen University), Aihua Lin(Guangzhou University of Chinese Medicine)
Cited by 51
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934
A Metagenomic Approach to Characterization of the Vaginal Microbiome Signature in Pregnancy
|PLoS ONE|2012|703
Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma
|Cell Research|2020|483
Responses of Plant Proteins to Heavy Metal Stress—A Review
|Frontiers in Plant Science|2017|426